7 results about "Therapy systemic" patented technology

The present invention relates to an antitumor adenovirus capable of evading the in vivo immune system. According to the present invention, the adenovirus comprising a nucleic acid coding for a transferrin-binding domain of the present invention exhibits notably increased effects of infecting and killing tumor cells, exhibits increased binding to transferrin, thereby evading an in vivo immune response and thus increasing the plasma half-life, has a systemic therapeutic effect by being specifically delivered to cancer cells, is capable of being topically delivered, and has excellent selectivity, thereby exhibiting the effect of notable antitumor efficacy, and thus may be usefully employed as an anticancer composition or an anticancer adjuvant for various carcinomas.

The present invention is in the field of molecular subtyping of tumor samples and therapy guidance. The present invention relates to methods, arrays, prognostic assays, systems and uses thereof for prediction of the response or resistance to and / or benefit from a systemic treatment, in particular adjuvant or neoadjuvant chemotherapy, of a subject suffering from a HR+ and HER2− breast cancer, based on the measurement(s) of expression level(s) of three or more markers in tumor samples of said subject. Equally, the present invention relates to methods, arrays, prognostic assays, systems and uses thereof for prediction of the outcome benefit from a systemic treatment, in particular adjuvant or neoadjuvant chemotherapy, of a subject suffering from a HR+ and HER2− breast cancer, based on the measurement(s) of expression level(s) of three or more markers in tumor samples of said subject.

The invention belongs to the technical field of medical treatment, and discloses an initial non-resectable hepatocellular carcinoma postoperative drug-free monitoring method based on complete pathology remission, and the method comprises the following steps: selecting a patient; all patients are subjected to systemic treatment or combined transarterial treatment; dosage adjustment and temporary interruption of treatment are allowed according to adverse reaction conditions; the transcatheter treatment comprises transcatheter arterial chemoembolization TACE and hepatic arterial perfusion chemotherapy HAIC; in assessing the tumor response, contrast enhanced computed tomography (CT) or magnetic resonance imaging (MRI) is used every 6 to 8 weeks, based on the mRECIST and RECIST 1.1 criteria; postoperative adjuvant therapy is usually started 4-8 weeks after an operation, and is usually based on a preoperative transformation treatment scheme; the adverse reactions are evaluated by comparing the baseline value changes during the first post-operative follow-up with the subsequent follow-up.

The present invention provides methods for increasing the systemic bioavailability of a polypeptide therapeutic administered orally, via oral gavage, via nasogastric gavage, or intragastric administration, comprising administering the polypeptide therapeutic to the stomach of a human or non-human animal as part of one or more dosage forms together with an alginate oligomer and, optionally, a gastrointestinal permeation enhancer, wherein the one or more dosage forms do not, in addition to the polypeptide therapeutic, the alginate oligomer, and, if used, the gastrointestinal permeation enhancer, have a coating that provides substantial protection from the gastric environment. Such methods allow for the systemic treatment or prevention of diseases, conditions, or complications thereof that are responsive to or prevented by the polypeptide therapeutic via oral, oral gavage, via nasogastric gavage, or intragastric administration. Further provided are compositions comprising an alginate oligomer, a polypeptide therapeutic, and, optionally, a gastrointestinal permeation enhancer for use in such methods.

The invention describes a novel method and alcohol-based compositions for the topical treatment of Treponema-associated digital dermatitis in equines, containing at least one or more different monohydric alcohol compounds, characterized in that they additionally contain at least one or more surfactants, one or more polyhydric alcohol compounds, and may further contain, depending on the intended use, one or more aldehyde compounds, one or more organic and / or inorganic acids, one or more organic and / or inorganic basic compounds, one or more inorganic and / or organic salts, one or more compounds from the group of essential oils, and active ingredients that are subject to drug regulations and, in particular, originate from the group of antibiotics. These products can also be used as cleaning and disinfecting agents on keratinized body parts and the coat of horses colonized with pathogenic organisms, as sprays, bath additives, or in gel form. The procedure particularly includes therapy in combination with the systemic administration of antimicrobial agents from the macrolide or penicillin groups.

Methods, devices and systems are provided to analyze the immunologic response of patients at various times before, during and / or after immunomodulating therapy, particularly treatment with specialized pulsed electric field energy. In some embodiments, such methods, devices and systems include a laboratory developed test that utilizes a patient tumor biopsy sample and a series of blood draws to determine whether the locoregional therapy (with or without additional systemic therapies, or systemic therapies-alone) was sufficient to facilitate an increase in tumor-specific antibody production. In some embodiments, the focus is on evaluation of baseline antibody levels, prior to any treatment, and changes in levels of antibodies to given antigens, especially in response to a given therapy treatment. In such embodiments, this antibody testing is performed prior to treatment. The treatment, such as delivery of specialized PEF energy to a target tissue, is then performed and antibody levels are checked at one or more later timepoints to detect changes in the presence of antibodies and therefore response to therapy.

The presented invention is meant to replace all traditional treatments for the skin (topical, systemic), It is developed for oily skin, but can be used by anyone. Unlike traditional treatment it is effective all of the time. Consists of a 2-phase solution, emulsion or liposomes, that is topical. The 2 phases can be adjusted independently, as long as droplet size are smaller than skin pores (20-150μm) and have the right surface polarity to enter skin pores for effective treatment. It is better than existing systemic treatments by the ratio of drug solubilities, typically by 100x. By reducing the drug phase, droplet size is reduced for easier skin pore emtry and if organic don't cause skin burns.